How long does Zepbound take to work? a week-by-week timeline

Zepbound takes weeks to show measurable weight loss and months to reach its full effect, because the dose starts low and rises in steps. In a SURMOUNT-1 analysis, 62.1% of people on tirzepatide had lost at least 5% of their body weight by week 8, and in the trial the average loss kept growing through week 72, when it reached 15.0% to 20.9% depending on dose.

Wegovy follows a similar pattern on a longer dose ramp. Every number below is a trial average from people who also got diet and activity counseling. Your own pace can be faster or slower.

The timeline at a glance

Sources: Zepbound label sections 2 and 14 (rev. 08/2026); Kokkinos et al. 2026; Ard et al. 2025; SURMOUNT-5 post hoc 2026.

Post hoc analyses look back at a finished trial and were not its planned endpoints, and all three cited here include Lilly employees as authors. Treat them as a guide to the general pattern, not a forecast.

Why the first months are slow

Three things in the label explain the slow start.

• The starting dose is a ramp, not a treatment dose. Zepbound begins at 2.5 mg a week for 4 weeks, and the label says 2.5 mg “is not approved as a maintenance dosage.” The step-ups exist to reduce stomach side effects.
• Each step takes at least 4 weeks. The dose rises by 2.5 mg no sooner than every 4 weeks. Approved maintenance doses are 5 mg, 10 mg or 15 mg, so 15 mg cannot start until after 20 weeks on the fastest schedule. In SURMOUNT-1, the escalation period lasted up to 20 weeks before the maintenance period began.
• Drug levels take time to settle. Tirzepatide levels reach a steady state after 4 weeks of weekly doses, and its half-life is about 5 to 6 days.

If side effects are hard to live with, the label lets your clinician keep you at a dose longer or choose a lower maintenance dose. That can slow weight loss, and that is a normal trade-off.

Months 1 and 2: early changes

The Zepbound label does not publish an average for the first month. The earliest checkpoint we found is week 8, after 4 weeks at 2.5 mg and 4 weeks at 5 mg. In a post hoc analysis of SURMOUNT-1, 62.1% of people on tirzepatide had lost 5% or more by then. Those “early responders” averaged 7.9% at week 8; everyone else averaged 3.1% (Kokkinos et al.). Both groups kept losing weight through week 72, reaching averages of 23.3% and 14.6%.

Month 3: the 12-week check

Many clinicians look at weight loss around 12 weeks. In a separate SURMOUNT-1 analysis of 1,545 people who took at least 75% of their doses, 82% had lost 5% or more by week 12 (Ard et al.).

The other 18%, called late responders, were not left behind for good. By week 24, 70% of them had reached 5%, and by week 72, 90% had. On average it took them 24.8 weeks to get there. The authors concluded that continuing treatment well beyond 12 weeks may let more people reach a meaningful loss, which matters for a drug whose dose ramp can last 20 weeks. If your progress is slow at 3 months, discuss your dose and plan with your clinician before stopping.

Months 4 to 9: the steepest stretch

Once people reach their maintenance dose, losses add up quickly. In SURMOUNT-5, which compared tirzepatide with semaglutide, 44% of people on tirzepatide had lost 15% or more by week 24, vs 21% on semaglutide (SURMOUNT-5 post hoc).

In SURMOUNT-4, everyone took Zepbound for 36 weeks before some were switched to placebo. The 670 people who completed that phase, 93% of them on 15 mg, had lost 20.9% of their body weight on average by week 36.

Months 12 to 18: where the averages land

The label’s main trial, SURMOUNT-1, ran 72 weeks in 2,539 adults without diabetes. Average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo (Jastreboff et al.). On 15 mg, 90.9% lost at least 5% and 56.7% lost at least 20%.

In adults with type 2 diabetes (SURMOUNT-2), losses were smaller: 12.8% on 10 mg and 14.7% on 15 mg vs 3.2% on placebo at 72 weeks.

How long does Wegovy take to work?

Wegovy has a longer ramp: 0.25 mg for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg, reaching the 2.4 mg maintenance dose at week 17.

• Week 20: In STEP 4, people who reached 2.4 mg and completed a 20-week run-in had lost 10.6% on average (Rubino et al.).
• Week 68: In STEP 1, average weight loss was 14.9% vs 2.4% on placebo. 86.4% lost at least 5%, 69.1% at least 10% and 50.5% at least 15% (Wilding et al.).

The daily Wegovy pill steps up every 30 days from 1.5 mg to 4 mg and 9 mg, reaching 25 mg on day 91. In the trial on its label (OASIS 4), people lost 13.6% at 64 weeks vs 2.4% on placebo, and 76.3% lost at least 5% (Wegovy label, rev. 06/2026).

How long does Ozempic take to work?

Ozempic is approved to improve blood sugar in type 2 diabetes and to lower heart and kidney risks in that group. It is not approved for weight loss, so using it for weight loss is off-label. It starts at 0.25 mg for 4 weeks, and semaglutide reaches steady levels after 4 to 5 weeks at a dose. In a 30-week trial, HbA1c fell 1.4 points on 0.5 mg and 1.6 points on 1 mg vs 0.1 on placebo. Weight fell 3.8 kg and 4.7 kg vs 1.2 kg (Ozempic label, rev. 05/2026). Mounjaro, tirzepatide approved for type 2 diabetes, also starts at 2.5 mg and rises in 2.5 mg steps at least 4 weeks apart; weight loss is not an approved use for it.

What happens if you stop

Results last only while treatment continues, on average. In SURMOUNT-4, people switched from Zepbound to placebo at week 36 regained 14.0% of their weight by week 88, while those who stayed on it lost another 5.5%. In STEP 4, people switched off Wegovy at week 20 regained 6.9% by week 68, while those who stayed on lost another 7.9%. Plan with your clinician before stopping.

Safety: the boxed warning comes first

Zepbound, Wegovy, Ozempic and Mounjaro carry a boxed warning for thyroid C-cell tumors. Semaglutide caused these tumors in mice and rats, and tirzepatide in rats; it is unknown whether they do in humans. They are not for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Stomach side effects are most common during dose increases. The labels also warn about kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions and risks under anesthesia. Our GLP-1 side effects guide has the rates.

Compounded semaglutide and tirzepatide were not part of these trials. A compounding pharmacy prepares them, and they aren’t FDA-approved, so none of these timelines describe them.

The bottom line

Expect the first 2 to 3 months to be the slow part while your dose climbs. In the trials, most people on tirzepatide had lost 5% by week 12, the steepest losses came after the maintenance dose, and averages reached about 15% to 21% at 72 weeks. Wegovy averaged 14.9% at 68 weeks. To compare the two drugs, see Wegovy vs Zepbound, and for eating well while you wait, see our GLP-1 diet guide.